Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16188276 | 0.91 | TSHR (0.56) | TSHRKDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL1231574 | 0.89 | TSHR (0.57) | TSHRALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL456337 | 0.82 | ALDH1A1 (0.44) | TSHRALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL3131935 | 0.81 | TSHR (0.63) | TSHRKDM4EALDH1A1LMNAHTT | |
| SCHEMBL3124612 | 0.80 | TSHR (0.62) | TSHRKDM4EALDH1A1CA12CA9 | |
| SCHEMBL4264787 | 0.79 | TSHR (0.60) | TSHRKDM4EALDH1A1CA12CA9 | |
| SCHEMBL5826839 | 0.79 | TSHR (0.60) | TSHRKDM4EALDH1A1CA12CA9 | |
| SCHEMBL4551788 | 0.78 | POLB (0.60) | TSHRKDM4EALDH1A1LMNAHTT | |
| Hydrochloric Acid SCHEMBL28282314 | 0.78 | XDH (0.46) | ALDH1A1LMNAHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL5875796 | 0.77 | MEN1 (0.60) | TSHRKDM4EALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005520-B2 | Process for the preparation of pyrazolopyrimidinones | PFIZER INC. (US) | 2006-02-28 | — | — | US | disclosed |
| EP-1292586-B1 | PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIMIDINONES | PFIZER LTD (GB) | 2004-08-04 | — | — | EP | disclosed |
| US-20040106796-A1 | Novel process for the preparation of pyrazolopyrimidinones | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| US-6667398-B2 | Reacting a benzamidine compound with a amide substituted pyrazole compound | PFIZER INC | 2003-12-23 | — | — | US | disclosed |
| EP-1292586-A1 | PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIMIDINONES | Pfizer Limited (GB) | 2003-03-19 | — | — | EP | disclosed |
| US-20020013464-A1 | Novel process for the preparation of pyrazolopyrimidinones | PFIZER INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001098284-A1 | PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIMIDINONES | PFIZER LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106796-A1 | Novel process for the preparation of pyrazolopyrimidinones | CYP4F3, CYP3A4, NDUFS3 | TSHR 1691/4885KDM4E 2782/4885ALDH1A1 812/4885 |
| US-20020013464-A1 | Novel process for the preparation of pyrazolopyrimidinones | CYP4F3, CYP3A4, NDUFS3 | TSHR 1691/4885KDM4E 2782/4885ALDH1A1 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.